Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules that hijack the ubiquitin proteasome system (UPS) for targeted protein degradation.
• PROTACs offer advantages over traditional small molecule inhibitors (SMIs) including sub-stoichiometric degradation, targeting of undruggable proteins, and enhanced selectivity.

Purpose of the Study:

• To systematically review existing PROTACs for hematologic malignancies.
• To discuss strategies for enhancing PROTAC safety in clinical applications.
• To propose the use of single-cell RNA sequencing data for developing cell type-specific PROTACs.

Main Methods:

• Literature review of PROTACs relevant to hematologic malignancies.
• Analysis of strategies for improving PROTAC safety.
• Proposal for utilizing human pan-tissue single-cell RNA sequencing data.

Main Results:

• PROTACs demonstrate significant efficacy and specificity in degrading oncogenic proteins, with several advancing to clinical trials.
• Identification of hematopoietic cell type-specific E3 ligases is crucial for developing targeted PROTACs.

Conclusions:

• PROTACs represent a promising therapeutic strategy for hematologic malignancies.
• Developing tumor-specific PROTACs by leveraging cell-type specific E3 ligases can mitigate on-target toxicities and improve safety.
• PROTACs hold potential for safer and more effective cancer treatments.